|
Authors | Year | Study type | Disease | Treatment | Number of patients | Length of preceding therapy | Outcome after withdrawal |
|
George et al. [25] | 1996 | Retrospective | UC | 6-Mercaptopurine | 105 | | Relapse: 87% |
|
Fraser et al. [26] | 2002 | Retrospective | UC and CD | Azathioprine | 222 IBD (143 UC and 79 CD) | | Relapse at 1 year: 37%; 2 years: 56%; 3 years: 66%; 4 years: 72%; 5 years: 75% |
|
Cassinotti et al. [27] | 2009 | Retrospective | UC | Azathioprine | 127 | Median: 47 months | Relapse at 1 year: 35%, 2 years: 49%, 3 years: 59%, 4 years: 61%, 5 years: 65% |
|
Kim et al. [28] | 1999 | Retrospective | CD | 6-Mercaptopurine | 36 | ≥6 months | Relapse at 1 year: 36% (versus 29% in those on drug), 2 years: 71% (versus 45% in those of drug), 3 years: 85% (versus 55% in those on drug), 5 years: 85% (versus 61% in those on drugs) |
|
Bouhnik et al. [16] | 1996 | Retrospective | CD | Azathioprine/6-mercaptopurine | 42 | >6 months | Relapse at 1 year: 38%, 3 years: 61%, 5 years: 75% |
|
Holtmann et al. [29] | 2006 | Retrospective | UC and CD | Azathioprine/6-mercaptopurine | 160 CD and 208 UC | <3 years, 3-4 years or >4 years | Median disease flare/year: in CD: 0 in all duration groups; in UC: <3 years: 0, 3-4 years: 0.48; >4 years: 0.96 |
|
Fraser et al. [19] | 2002 | Retrospective | CD and UC | Methotrexate | 19 | Mean: 17.1 months | Relapse at 6 months: 58%, 12 months: 79%, 18 months: 84% |
|
Steenholdt et al. [30] | 2012 | Retrospective | UC | Infliximab | 28 | | Relapse at 1 year: 25%, 10 years: 88% |
CD | 53 | | Relapse at 1 year: 39%, 4.5 years: 60% |
|
Farkas et al. [31] | 2014 | Prospective observational | UC | Infliximab or adalimumab | 22 | 1 year | Relapse at 1 year: 59% |
CD | 41 | Relapse at 1 year: 78% |
|
Domènech et al. [20] | 2005 | Retrospective | CD | Infliximab | 23 luminal CD patients receiving only induction therapy (3 infusions) | 6 weeks | Relapse at 2 months: 100% in partial remission group; 6 months: 28% in complete remission group |
23 luminal or perianal CD patients receiving infusions every 8 weeks | 1 year | Relapse at a median of 8.8 months: 48% |
|
Schnitzler et al. [21] | 2009 | Prospective observational | CD | Infliximab | 110 | Median: 6.2 months | Median length of remission: 47.3 months |
|
Waugh et al. [32] | 2010 | Retrospective | CD | Infliximab | 48 | Median: 15.6 months | Relapse at a median of 477 days: 50%, at a median of 4.1 years: 65% |
|
Louis et al. [22] | 2012 | Prospective observational | CD | Infliximab | 155 | ≥1 year | Relapse at 1 year: 43.9%, 2 years: 52.2% |
|
Molnár et al. [23] | 2013 | Prospective observational | CD | Infliximab or adalimumab | 121 | 1 year | Relapse at 1 year: 45%, 2 years: 88% |
|
Farkas et al. [24] | 2013 | Prospective observational | UC | Infliximab | 51 | 1 year | Relapse at 1 year: 35% |
|